Injunction Clears Early Threat To TAP's Lupron Depot

Law360, New York (February 28, 2006, 12:00 AM EST) -- Generic drug maker QLT Inc. has been dealt yet another blow in its effort to maintain its presence in the market for prostate cancer treatments, with a federal judge issuing a damaging injunction and setting the stage for a drawn-out appeal.

The injunction is the latest in a string of setbacks for Canada-based QLT, which drew fire from plaintiff TAP Pharmaceutical Products Inc. in November 2003, when QLT won approval from the U.S. Food and Drug Administration to develop and market its Eligard product.

TAP argues...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.